FDA approves third over-the-counter naloxone nasal spray, expanding direct access to emergency opioid overdose treatment

The Food and Drug Administration has approved a third over-the-counter naloxone nasal spray product for emergency treatment of opioid overdoses, in an action the agency said could improve access and reduce costs. The approval, announced Tuesday, covers another version of Rextovy, a naloxone nasal spray with a 4 milligram dose for use in suspected opioid overdose emergencies.

According to the FDA as reported by The Hill, the newly approved product is intended for non-prescription purchase, allowing consumers to obtain naloxone without a clinician order. The agency said the product may be bought directly at pharmacies and convenience stores and also through online retail channels.

Naloxone is an opioid antagonist used to rapidly reverse the effects of opioid overdoses while emergency medical services are contacted or otherwise engaged. Overdose reversal products like naloxone are widely used in community, workplace, and household settings to provide immediate intervention before paramedics arrive.

The FDA has approved multiple over-the-counter naloxone nasal spray formulations in recent years as part of a broader effort to make the medicine more available to the public. With each additional OTC approval, regulators can expand the set of brands and formulations that pharmacies and retailers may stock for walk-in customers and online orders.

The Hill reported that FDA officials said the OTC status of the product may help save lives and reduce costs. The agency’s stated framing centered on expanding access by removing barriers associated with obtaining a prescription, particularly for people who may not know where or how quickly to secure naloxone.

It was not immediately clear from the available reporting when the product would begin widespread retail distribution or how pricing would vary by retailer or region. Additional details on labeling, packaging, and distribution timelines would typically follow FDA approval and retail listings, according to standard implementation practices for drug approvals.